Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

How to choose proper local treatment in men aged ≥75 years with cT2 localized prostate cancer?

Jin K, Qiu S, Li J, Zheng X, Tu X, Liao X, Yang Y, Yang L, Wei Q.

Cancer Med. 2019 Jul;8(7):3370-3378. doi: 10.1002/cam4.2221. Epub 2019 May 8.

2.

Local Therapy Improves Survival in Metastatic Prostate Cancer.

Leyh-Bannurah SR, Gazdovich S, Budäus L, Zaffuto E, Briganti A, Abdollah F, Montorsi F, Schiffmann J, Menon M, Shariat SF, Fisch M, Chun F, Steuber T, Huland H, Graefen M, Karakiewicz PI.

Eur Urol. 2017 Jul;72(1):118-124. doi: 10.1016/j.eururo.2017.03.020. Epub 2017 Apr 3.

PMID:
28385454
3.

The Effect of Lymph Node Dissection in Metastatic Prostate Cancer Patients Treated with Radical Prostatectomy: A Contemporary Analysis of Survival and Early Postoperative Outcomes.

Mazzone E, Preisser F, Nazzani S, Tian Z, Bandini M, Gandaglia G, Fossati N, Montorsi F, Graefen M, Shariat SF, Saad F, Briganti A, Karakiewicz PI.

Eur Urol Oncol. 2018 Nov 22. pii: S2588-9311(18)30191-3. doi: 10.1016/j.euo.2018.10.010. [Epub ahead of print]

PMID:
31411992
4.

The impact of age at the time of radiotherapy for localized prostate cancer on the development of second primary malignancies.

Krasnow RE, Rodríguez D, Nagle RT, Mossanen M, Kibel AS, Chang SL.

Urol Oncol. 2018 Nov;36(11):500.e11-500.e19. doi: 10.1016/j.urolonc.2018.06.007. Epub 2018 Sep 21.

PMID:
30249519
5.

Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion.

Preisser F, Bandini M, Marchioni M, Nazzani S, Tian Z, Pompe RS, Fossati N, Briganti A, Saad F, Shariat SF, Heinzer H, Huland H, Graefen M, Tilki D, Karakiewicz PI.

Prostate. 2018 May;78(6):469-475. doi: 10.1002/pros.23491. Epub 2018 Feb 19.

PMID:
29460290
6.

Survival after radical prostatectomy or radiotherapy for locally advanced (cT3) prostate cancer.

Bandini M, Marchioni M, Preisser F, Zaffuto E, Tian Z, Tilki D, Montorsi F, Shariat SF, Saad F, Briganti A, Karakiewicz PI.

World J Urol. 2018 Sep;36(9):1399-1407. doi: 10.1007/s00345-018-2310-y. Epub 2018 May 2.

PMID:
29717358
7.

Cancer-specific survival after metastasis following primary radical prostatectomy compared with radiation therapy in prostate cancer patients: results of a population-based, propensity score-matched analysis.

Shao YH, Kim S, Moore DF, Shih W, Lin Y, Stein M, Kim IY, Lu-Yao GL.

Eur Urol. 2014 Apr;65(4):693-700. doi: 10.1016/j.eururo.2013.05.023. Epub 2013 May 21.

8.

Mortality after prostate cancer treatment with radical prostatectomy, external-beam radiation therapy, or brachytherapy in men without comorbidity.

Nepple KG, Stephenson AJ, Kallogjeri D, Michalski J, Grubb RL 3rd, Strope SA, Haslag-Minoff J, Piccirillo JF, Ciezki JP, Klein EA, Reddy CA, Yu C, Kattan MW, Kibel AS.

Eur Urol. 2013 Sep;64(3):372-8. doi: 10.1016/j.eururo.2013.03.005. Epub 2013 Mar 13.

9.

Elderly patients aged ≥ 75 years with locally advanced prostate cancer may benefit from local treatment: a population-based propensity score-adjusted analysis.

Sheng W, Kirschner-Hermanns R, Zhang H.

World J Urol. 2019 Feb;37(2):317-325. doi: 10.1007/s00345-018-2389-1. Epub 2018 Jun 27.

PMID:
29951790
10.

Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort.

Cooperberg MR, Davicioni E, Crisan A, Jenkins RB, Ghadessi M, Karnes RJ.

Eur Urol. 2015 Feb;67(2):326-33. doi: 10.1016/j.eururo.2014.05.039. Epub 2014 Jul 2.

11.

Survival outcomes of locally advanced prostate cancer in patients aged < 50 years after local therapy in the contemporary US population.

Sheng W, Zhang H, Lu Y.

Int Urol Nephrol. 2018 Aug;50(8):1435-1444. doi: 10.1007/s11255-018-1931-9. Epub 2018 Jul 7.

PMID:
29982959
12.

A competing risk analysis of cancer-specific mortality of initial treatment with radical prostatectomy versus radiation therapy in clinically localized high-risk prostate cancer.

Lee JY, Cho KS, Kwon JK, Jeh SU, Kang HW, Diaz RR, Ham WS, Koom WS, Keum KC, Choi YD.

Ann Surg Oncol. 2014 Nov;21(12):4026-33. doi: 10.1245/s10434-014-3780-9. Epub 2014 May 20.

PMID:
24841351
13.

Radical prostatectomy or radiotherapy reduce prostate cancer mortality in elderly patients: a population-based propensity score adjusted analysis.

Bandini M, Pompe RS, Marchioni M, Tian Z, Gandaglia G, Fossati N, Tilki D, Graefen M, Montorsi F, Shariat SF, Briganti A, Saad F, Karakiewicz PI.

World J Urol. 2018 Jan;36(1):7-13. doi: 10.1007/s00345-017-2102-9. Epub 2017 Oct 23.

PMID:
29063268
14.

The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.

Bianchi L, Nini A, Bianchi M, Gandaglia G, Fossati N, Suardi N, Moschini M, Dell'Oglio P, Schiavina R, Montorsi F, Briganti A.

Eur Urol. 2016 Jun;69(6):1142-8. doi: 10.1016/j.eururo.2015.12.010. Epub 2015 Dec 31.

PMID:
26749093
15.

The effect of race on survival after local therapy in metastatic prostate cancer patients.

Mazzone E, Bandini M, Preisser F, Nazzani S, Tian Z, Abdollah F, Soulieres D, Graefen M, Montorsi F, Shariat S, Saad F, Briganti A, Karakiewicz PI.

Can Urol Assoc J. 2019 Jun;13(6):175-181. doi: 10.5489/cuaj.5399.

16.

Long-term utility of adjuvant hormonal and radiation therapy for patients with seminal vesicle invasion at radical prostatectomy.

Moschini M, Sharma V, Gandaglia G, Dell'Oglio P, Fossati N, Zaffuto E, Montorsi F, Briganti A, Karnes RJ.

BJU Int. 2017 Jul;120(1):69-75. doi: 10.1111/bju.13683. Epub 2016 Nov 11.

17.

Cancer-Specific Mortality Among Korean Men with Localized or Locally Advanced Prostate Cancer Treated with Radical Prostatectomy Versus Radiotherapy: A Multi-Center Study Using Propensity Scoring and Competing Risk Regression Analyses.

Koo KC, Cho JS, Bang WJ, Lee SH, Cho SY, Kim SI, Kim SJ, Rha KH, Hong SJ, Chung BH.

Cancer Res Treat. 2018 Jan;50(1):129-137. doi: 10.4143/crt.2017.004. Epub 2017 Mar 8.

18.

Predicting survival of men with recurrent prostate cancer after radical prostatectomy.

Dell'Oglio P, Suardi N, Boorjian SA, Fossati N, Gandaglia G, Tian Z, Moschini M, Capitanio U, Karakiewicz PI, Montorsi F, Karnes RJ, Briganti A.

Eur J Cancer. 2016 Feb;54:27-34. doi: 10.1016/j.ejca.2015.11.004. Epub 2015 Dec 19.

PMID:
26707594
19.

Competing-risks mortality after radiotherapy vs. observation for localized prostate cancer: a population-based study.

Abdollah F, Sun M, Schmitges J, Thuret R, Tian Z, Shariat SF, Briganti A, Jeldres C, Perrotte P, Montorsi F, Karakiewicz PI.

Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):95-103. doi: 10.1016/j.ijrobp.2011.11.034. Epub 2012 Feb 11.

PMID:
22330991
20.

Adjuvant Radiotherapy in Prostate Cancer Patients Treated with Surgery: The Impact of Age and Tumor Characteristics.

Abdollah F, Karakiewicz PI, Gandaglia G, Dalela D, Klett DE, Shiffmann J, Montorsi F, Briganti A, Saad F, Graefen M, Peabody JO, Menon M, Sun M.

Eur Urol Focus. 2015 Sep;1(2):191-199. doi: 10.1016/j.euf.2015.06.008. Epub 2015 Jul 10.

PMID:
28723433

Supplemental Content

Support Center